Press

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

Dec 7 • 2 min read

Reunion Neuroscience Inc. (NASDAQ: REUN | TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced it will be participating in the following investor conferences in December 2022. Stifel Canada’s The Future of Healthcare ConferenceDate: Wednesday, December 7, 2022Time: 2:00 p.m. ETFormat: PresentationWebcast: bit.ly/3AT6tFb Canaccord Genuity Symposium on New…

Mindset Pharma to Participate in Upcoming Conferences in December 2022

Dec 7 • 2 min read

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that James Lanthier, CEO of Mindset, and Joseph Araujo, CSO, will participate in two upcoming conferences: For more information about…

Irwin Naturals Files Q3 2022 Financials

Dec 7 • 5 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) announced the Company filed results for its third quarter of fiscal 2022, the period ended September 30, 2022 on www.sedar.com. “Despite cost pressures continuing through the quarter, we were able to grow our Gross Margins by +4.8% over Q3 2021. The Gross Margin increase can be attributed…

Enthea Announces Nationwide Rollout to Offer Psychedelic Therapy as a Workplace Benefit

Dec 6 • 5 min read

Enthea, the first provider of insurance plans for psychedelic healthcare, announces today its successful $2M seed round raise, led by Tabula Rasa Ventures, the first psychedelic accelerator for early-stage startups. The funds will be used to launch its services into 40 markets across the U.S. next year as well as grow Enthea’s customer base and…

PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio

Dec 6 • 2 min read

PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the filing of four new U.S. Patent Cooperation Treaty (PCT) Patent Applications seeking to convert five provisional patent applications. This brings the total number…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441